Fwd: [en] IACM-Bulletin of 15 August 2010

1 view
Skip to first unread message

David Knowles

unread,
Oct 5, 2010, 11:53:41 AM10/5/10
to virgin-islands-m...@googlegroups.com


---------- Forwarded message ----------
From: <in...@cannabis-med.org>
Date: Sun, Aug 15, 2010 at 9:13 AM
Subject: [en] IACM-Bulletin of 15 August 2010
To: e...@cannabis-med.org


--------------------------------------------------------
IACM-Bulletin of 15 August 2010
--------------------------------------------------------

* Germany/USA: Three quarters of citizens in the USA and
Germany support the medical use of cannabis
* USA: Propositions on regulations for the medical use of
cannabis in Washington D.C.

1.

Germany/USA: Three quarters of citizens in the USA and
Germany support the medical use of cannabis

According to a poll conducted by Emnid Institute there is a broad
support in Germany when it comes to the medical use of
cannabis. Of 1,001 interviewees asked by phone 76 per cent said
that the use of cannabis for medicinal purposes should be allowed
while only 18 per cent disagreed and 6 per cent had no opinion on
this issue. The poll consisting of two questions was ordered by the
German Association for Cannabis as Medicine (ACM).
According to the answers to the second question 65 per cent of
Germans think that a treatment with the cannabis compound
dronabinol (THC) should be paid by the health insurances, which
currently is usually not the case.

Support for the medical use of cannabis was highest among highly
educated people, men, people between 50 and 60 years of age,
and partisans of the small political parties, Greens (90 per cent),
Liberals (85 per cent) and the Left (85 per cent). More than three
quarters of the large parties Social Democrats (83 per cent) and
Christian Democrats (77 per cent) also supported the medical use
of cannabis. The lowest support was observed among non-voters
(72 per cent). These results are in agreement with a recent
Rasmussen poll in the USA showing that 75 per cent of
Americans support the use of cannabis for medicinal purposes if
prescribed by a physician.

More at:
- http://www.cannabis-med.org/german/emnid_2010.pdf
- http://www.aerztezeitung.de/medizin/krankheiten/neuro-
psychiatrische_krankheiten/multiple_sklerose/article/615041/umfra
ge-kaum-vorbehalte-cannabis-medizin.html?sh=4&h=-1265806251

- http://www.reuters.com/article/idUS96644+05-Aug-
2010+MW20100805

- http://www.cannabis-med.org/german/acm-
mitteilungen/ww_de_db_cannabis_artikel.php?id=65

(Sources: Reuters of 5 August 2010, German Press Agency of 13
August 2010, Association for Cannabis as Medicine)

2.

USA: Propositions on regulations for the medical use of cannabis
in Washington D.C.

Stores that sell medical cannabis in Washington won't be allowed
to advertise their wares with giant cannabis leaves, and the
packages they dispense will have to display a warning on health
risks. Those are just two of more than 300 proposed regulations
published on 6 August to implement a new medical cannabis law
in the city. The regulations, which range from how the drug may
be grown to what dispensaries can look like, are the first step in
setting out how Washington residents will be able to obtain
cannabis for medical use.

The newly proposed regulations, written by the mayor's office, are
now open for comment by the public. Patients are not expected to
be able to buy cannabis in the city until 2011. Advocates for the
medical use of cannabis are already questioning some of the
regulations and asking why it would take so long for them to go
into effect. For example, they take issue with regulations that put
cannabis growers and sellers under the authority of the same city
agency that handles liquor licenses. Critics say that medical
cannabis should be regulated by the health department, which will
also oversee patient registration.

More at:
http://www.msnbc.msn.com/id/38595694/ns/health

(Source: Associated Press of 6 August 2010)

3.

News in brief

***USA: Colorado
The state of Colorado made about 7 million dollars (about 5.5
million Euros) in fees from the more than 700 dispensary owners
who applied for their state license. The state also received
approximately 1,300 license applications for growing operations or
related medical cannabis businesses. Under a new bill of June
2010 businesses working in the field of medical cannabis have to
apply for a state license. (Source: Denver Daily News of 4
August 2010)

***Science: Pain
According to a study by the pharmaceutical company
AstraZeneca a peripherally restricted cannabinoid receptor
agonist (AZ11713908) produced robust pain reducing effects in
mouse models of inflammatory and neuropathic pain. There were
no effects on the central nervous system. (Source: Yu XH, et al.
Pain. 2010 Aug 7. [in press])

***Science: Obsessive-compulsive disorder
According to a study at the University of São Paulo, Brazil, the
natural cannabinoid cannabidiol (CBD) is effective in a mouse
model of obsessive-compulsive disorder, a test where the animals
bury marbles. CBD (15, 30 and 60 mg/kg body weight) induced a
significant decrease in the number of buried marbles compared
with controls (34,  41 and 48 per cent, respectively). This effect
was blocked by a CB1 receptor antagonist. (Source: Casarotto
PC, et al. Behav Pharmacol 2010;21(4):353-8.)

***Science: Sleep
At the Johns Hopkins Medical Institutions in Baltimore, USA, the
effects of cessation of cannabis use on sleep where investigated
in 18 heavy users until day 13 of abstinence. During the whole
period total sleep time, sleep efficiency, and amount of so-called
REM sleep declined, while wake after sleep onset and periodic
limb movements during sleep increased. (Source: Bolla KI, et al.
Sleep Med. 2010 Aug 2. [in press])

***Science: Cancer
According to a study at the Italian Institute for Digestive Diseases
in Bari, Italy, the endocannabinoid anandamide reduced the level
of so-called polyamines (putrescine, spermidine und spermine) in
human colon cancer cells and inhibited cancer cell proliferation.
These effects were mediated by the CB1 receptor. Polyamines
are compounds that play an important role in cell proliferation.
(Source: Linsalata M, et al. Anticancer Res 2010;30(7):2583-9.)

***Science: Irritable bowel syndrome
According to an animal study at the Huazhong University of
Science and Technology in Wuhan, China, chronic mild stress
causes hypersensitivity in the bowel. This hypersensitivity was
reduced in the study by a cannabinoid (ACEA) and this effect
was mediated by the CB1 receptor. Irritable bowel syndrome is
associated with hypersensitivity of the bowel. Researchers
concluded that "there is a key contribution of peripheral CB1
receptors involved in the maintenance of visceral hyperalgesia."
(Source: Shen L, et al. J Neurogastroenterol Motil 2010;16(3):281-
90.)

***Science: Cancer
Researchers at the University of Rostock, Germany, investigated
the mechanisms of the anti-cancer effects of cannabidiol (CBD)
in lung cancer cells. They noted a significant decrease of
plasminogen activator inhibitor-1. They concluded that their "data
provide evidence for a hitherto unknown mechanism underlying
the anti-invasive action of cannabidiol on human lung cancer
cells." (Source: Ramer R, et al. Pharm Res. 2010 Jul 29. [in
press])

***Science: Time
Researchers at Yale University in New Haven, USA, investigated
the effects of cannabinoids on the circadian clock of the brain.
Cannabinoids did not alter the endogenous free-running circadian
rhythm in the mouse brain, but did attenuate the ability of the
circadian clock to entrain to light zeitgebers. (Source: Acuna-
Goycolea C, et al. J Neurosci 2010;30(30):10061-6.)

***Science: Neuroprotection
According to a Chinese group working with rats the
neuroprotective effects of the synthetic cannabinoid WIN 55,212-
2 against the negative consequences of transient ischaemia
(reduced blood circulation) is through the activation of certain
extra-cellular kinases. Pre-treatment with the cannabinoid
protected the brain against transient ischaemia caused by
occlusion of the middle cerebral artery and increased levels of
these kinases (certain enzymes). (Source: Hu B, et al. Eur J
Pharmacol. 2010 Jul 27. [in press])

International Association for Cannabinoid Medicines (IACM)
Am Mildenweg 6
D-59602 Ruethen
Germany
Phone: +49 (0)2952-9708571
Fax: +49 (0)2952-902651
Email: in...@cannabis-med.org
http://www.cannabis-med.org

If you want to be deleted from or added to the IACM-Bulletin
mailing list or if you want to change your e-mail address please
visit
www.cannabis-med.org/english/subscribe.htm. You may choose
between different languages (English, German, French, Dutch,
Italian and Spanish).

The articles of the IACM-Bulletin can be printed, translated and
distributed freely for any non-commercial purposes, provided the
original work is properly cited. The source of the IACM-Bulletin
is "IACM, www.cannabis-med.org".

---------------------------------------------------------------------
To unsubscribe, e-mail: en-unsu...@cannabis-med.org
For additional commands, e-mail: en-...@cannabis-med.org




--
David Knowles

Safe Access to Medical cannabis in the US Virgin Islands
Decriminalize possession for
responsible adults
Agricultural Hemp
usvinorml.com
norml.org
safeaccessforamericans.org

www.usvinorml.com
www.norml.org
www.safeaccessforamericans.com
http://groups.google.co.vi/group/normlvi
www.cannabisMD.org
Reply all
Reply to author
Forward
0 new messages